Bifidobacterium animalis lactis subspecies for reducing Aβ42 deposition and application thereof

The animal Bifidobacterium milk subspecies IOB-LO7 reduced Aβ42 deposition, which solved the problems of neuroinflammatory and cognitive decline caused by Aβ42 deposition in Alzheimer's disease, and achieved significant neuroprotection and cognitive function recovery effects.

CN118726212BActive Publication Date: 2024-11-12TIANJIN INNOORIGIN BIOLOGICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411230717.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-11-12
Estimated Expiration
2044-09-04

AI Technical Summary

Technical Problem

Aβ42 deposition in Alzheimer's disease patients leads to neuroinflammatory and cognitive function decline. The prior art is difficult to effectively reduce Aβ42 deposition, affecting the therapeutic effect.

Method used

Provides an animal Bifidobacterium milk subspecies IOB-LO7 that reduces Aβ42 deposition, classified as Bifidobacterium animalis subsp.lactis, by preparing bacterial powder and epibiotics, to prepare drugs to protect nerve cells, reduce the cerebral cortex and hippocampus. The content of Aβ42 in the medium can remove Aβ amyloid plaques, regulate intestinal flora metabolites, and reduce intestinal mucosal barrier damage.

Benefits of technology

It significantly reduces the aggregation of Aβ42 in brain tissue, improves neuronal communication, reduces brain inflammatory response, improves synaptic transmission, restores cognitive function, and relieves Alzheimer's symptoms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118726212B_ABST
    Figure CN118726212B_ABST
Patent Text Reader

Abstract

The present invention provides a bifidobacterium lactis subspecies for reducing Aβ42 deposition and its application, which relates to the field of microorganisms. The bifidobacterium lactis subspecies is bifidobacterium lactis subspecies IOB-LO7, which is classified as Bifidobacterium animalis subsp.lactis , was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on December 23, 2021, referred to as CGMCC, with the deposit number CGMCC No. 24185. It can help restore cognitive function and improve Alzheimer's disease by reducing the content of Aβ42 in the cerebral cortex and hippocampus, clearing Aβ amyloid plaques, improving communication between neurons, reducing brain neuroinflammation, and protecting nerve cells. In addition, it can also improve the imbalance of intestinal flora caused by Alzheimer's disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of microorganisms, and in particular to Bifidobacterium animalis subspecies lactis capable of reducing Aβ42 deposition and applications thereof. Background Art

[0002] Alzheimer's disease is a common chronic degenerative disease of the central nervous system, accounting for 60% to 70% of all Alzheimer's disease cases. Alzheimer's patients typically experience cognitive impairment, behavioral disorders, memory loss, language impairment, and personality changes. The number of dementia patients in my country is enormous, with approximately 10 to 11 million people over the age of 60, of whom 60% to 80% have Alzheimer's disease.

[0003] The onset of Alzheimer's disease is caused by multiple neurological damages, such as Aβ aggregation, tau protein hyperphosphorylation, oxidative stress, and inflammatory responses. Neuropathological manifestations in Alzheimer's patients primarily include extracellular senile plaques (SPs), intracellular neurofibrillary tangles (NFTs), synaptic loss, and exacerbated neuroinflammatory responses mediated by microglia and astrocytes.

[0004] Amyloid deposition is the core pathological hallmark of Alzheimer's disease. Its accumulation in the brain, forming plaques, triggers a series of neuroinflammatory processes and, through bidirectional interactions between the brain and gut, alters the structure of the gut microbiome. Recently, a hypothesis has emerged that the pathogenesis of Alzheimer's disease may be linked to an imbalance in the gut microbiome. Disturbances in the gut microbiome can lead to an imbalance in bacterial metabolites, such as lipopolysaccharide (LPS) and bacterial amyloid. These proteins can damage the gut barrier and increase its permeability. Bacterial LPS and amyloid cross the damaged intestinal mucosa and travel through the bloodstream to the central nervous system, where they increase the nucleation of Aβ aggregates and trigger a series of inflammatory responses. This, in turn, can damage the blood-brain barrier, causing neuroinflammation and neural damage, leading to neurodegeneration and ultimately Alzheimer's disease.

[0005] Probiotics have been shown to restore gut microbiota homeostasis, slow the progression of Alzheimer's disease, particularly the inflammatory response, and thus improve cognitive decline. Killed probiotics can affect the host gut microbiota by stimulating the host mucosal immune response, so intervention with probiotics or postbiotics is considered one of the best measures to prevent cognitive decline in Alzheimer's disease. Summary of the Invention

[0006] In view of the technical problems existing in the prior art, the present invention aims to provide a method for reducing Aβ42 deposition in animal Bifidobacterium lactis subspecies and its application, and specifically provides a method for reducing Aβ42 deposition in animal Bifidobacterium lactis subspecies IOB-LO7, which is classified asBifidobacterium animalis subsp.lactis , animal Bifidobacterium lactis subspecies 10B-LO7 bacterial powder, animal Bifidobacterium lactis subspecies 10B-LO7 postbiotics and applications thereof.

[0007] One of the purposes of the present invention is to provide a method for reducing the deposition of Aβ42 by Bifidobacterium animalis lactis subspecies, wherein the Bifidobacterium animalis lactis subspecies is Bifidobacterium animalis lactis subspecies IOB-LO7, and is classified as Bifidobacterium animalis subsp.lactis , and was deposited in the General Microbiology Center of China Culture Collection Administration of Microorganisms, abbreviated as CGMCC, on December 23, 2021, with the deposit number CGMCCNo.24185.

[0008] Specifically, the 16srDNA sequencing sequence of the animal bifidobacteria is:

[0009]

[0010] The second object of the present invention is to provide an application of Bifidobacterium animalis subsp. lactis, which can be used to prepare Bifidobacterium animalis subsp. lactis powder, Bifidobacterium animalis subsp. lactis postbiotics or medicines for protecting nerve cells.

[0011] Preferably, the method for preparing animal Bifidobacterium lactis subsp. lactis powder comprises the following steps:

[0012] First, prepare the fermentation liquid, lower the temperature of the centrifuge to 4~6°C, centrifuge the fermentation liquid at a centrifugal speed of 4000~6000rpm / min, and centrifuge for 20~30min. Take the precipitate after centrifugation, place it at -82~-80°C for pre-freezing for 2~3h, and then freeze-dry it at a drying temperature of -80~-60°C and a drying time of 24~48h to obtain animal Bifidobacterium lactis subspecies IOB-LO7 bacterial powder.

[0013] Preferably, the method for preparing animal Bifidobacterium lactis postbiotics comprises the following steps:

[0014] First, prepare the fermentation liquid, lower the temperature of the centrifuge to 4-6°C, centrifuge the fermentation liquid at a centrifugal speed of 4000-6000 rpm / min, and centrifuge for 20-30 minutes; sterilize the precipitate after centrifugation at 80-95°C for 20-25 minutes, place it at -82-80°C for pre-freezing for 2-3 hours, and then freeze-dry it to obtain animal Bifidobacterium lactis subsp. IOB-LO7 postbiotic powder; the drying temperature is set to -80-60°C, and the drying time is 24-48 hours.

[0015] Preferably, the method for preparing the fermentation broth comprises:

[0016] The animal Bifidobacterium lactis subsp. lactis 10B-LO7 stored in a cryopreservation tube is inoculated into 15-20 mL of TPY liquid culture medium, placed in a constant temperature incubator and cultured strictly anaerobically for 18-24 hours at a culture temperature of 35-38° C. to obtain a first-generation activated bacterial solution; the first-generation activated bacterial solution is inoculated into 50-60 mL of TPY liquid culture medium at an inoculation size of 3-5%, cultured at a temperature of 35-38° C., and cultured strictly anaerobically for 18-24 hours to obtain an activated bacterial solution; the activated bacterial solution is inoculated into 90-100 mL of TPY liquid culture medium at an inoculation size of 1-3%, cultured at a temperature of 35-38° C., and cultured strictly anaerobically for 18-20 hours to obtain a fermentation seed solution; the fermentation seed solution is inoculated into 800-1000 mL of TPY liquid culture medium at an inoculation size of 3-5%, cultured at a temperature of 35-38° C., and cultured strictly anaerobically for 18-20 hours to obtain a fermentation solution.

[0017] Preferably, the drug for protecting nerve cells comprises Bifidobacterium animalis subsp. lactis, Bifidobacterium animalis subsp. lactis bacterial powder or Bifidobacterium animalis subsp. lactis postbiotics.

[0018] Preferably, the viable bacteria count of the Bifidobacterium animalis subsp. lactis powder is 1×10 9 ~8×10 11 cfu / g, the number of viable bacteria of drugs that protect nerve cells is 1×10 9 ~8×10 11 cfu / g.

[0019] Beneficial effects of the present invention:

[0020] The present invention provides a method for reducing Aβ42 deposition by Bifidobacterium animalis subspecies lactis IOB-LO7, which is classified as Bifidobacterium animalis subsp.lactis The bacteria significantly reduced Aβ42 aggregation in brain tissue by reducing the levels of Aβ42 in the cerebral cortex and hippocampus by 42.1% to 64.9%. This, on the one hand, cleared Aβ amyloid plaques, significantly improved communication between neurons, and helped restore cognitive function. On the other hand, it reduced the brain inflammation triggered by the accumulation of Aβ42 in brain tissue, reducing damage to nerve cells. Simultaneously, reducing Aβ42 concentrations significantly improved synaptic transmission, accelerating the recovery of normal neural network function and effectively improving Alzheimer's disease. The bacteria also regulates intestinal flora metabolite imbalances, alleviates intestinal mucosal barrier damage in rats, improves intestinal barrier permeability, prevents the release and diffusion of harmful metabolites such as LPS, and reduces the nucleation of Aβ aggregates, thereby protecting the nervous system and reducing brain neuroinflammatory responses. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 Graph of the number of times rats crossed the platform;

[0022] Figure 2 Average speed of rats in the open field test;

[0023] Figure 3 Results of the total distance traveled by rats in the open field experiment;

[0024] Figure 4 Results of rat activity times in the open field experiment;

[0025] Figure 5 Results of Aβ42 content in rat hippocampus;

[0026] Figure 6 Results of Aβ42 content in the cerebral cortex;

[0027] Figure 7 Aβ42 protein plate deposition in rat hippocampus;

[0028] Figure 8 The relative area of ​​Aβ42 protein plaques in the rat hippocampus;

[0029] Figure 9 TLR4 relative transcription level;

[0030] Figure 10 MyD88 relative transcription level;

[0031] Figure 11 NLRP3 relative transcription level;

[0032] Figure 12 IL~1β relative transcription level;

[0033] Figure 13 IL~18 relative transcription level;

[0034] Figure 14 LPS content in rat feces;

[0035] Figure 15 LPS content in rat serum;

[0036] Figure 16 LPS content in rat hippocampus;

[0037] Figure 17 Pathological sections of rat small intestine tissue.

[0038] The bifidobacterium lactis subspecies provided by the present invention is named as Bifidobacterium lactis subspecies IOB-LO7, which is classified as Bifidobacterium animalis subsp.lactis , and was deposited in the General Microbiology Center of China Culture Collection Administration of Microorganisms, abbreviated as CGMCC, on December 23, 2021, with the deposit number CGMCCNo.24185. DETAILED DESCRIPTION

[0039] According to a first aspect of the present invention, there is provided an animal Bifidobacterium lactis subspecies that reduces Aβ42 deposition, wherein the Bifidobacterium lactis subspecies is Bifidobacterium lactis subspecies IOB-LO7, and is classified as Bifidobacterium animalis subsp.lactis , and was deposited in the General Microbiology Center of China Culture Collection Administration of Microorganisms, abbreviated as CGMCC, on December 23, 2021, with the deposit number CGMCCNo.24185.

[0040] In the present invention, the 16srDNA sequence of the animal Bifidobacterium lactis subsp.

[0041]

[0042] In a preferred embodiment of the present invention, the animal Bifidobacterium lactis subspecies IOB-LO7 reduces the content of Aβ42 in the cerebral cortex and hippocampus, clears Aβ amyloid plaques, improves communication between neurons, reduces brain neuroinflammation, protects nerve cells, helps restore cognitive function, and improves Alzheimer's disease.

[0043] In the present invention, animal Bifidobacterium lactis subspecies 10B-LO7 reduces the content of Aβ42 in the cerebral cortex and hippocampus, greatly reduces the aggregation of Aβ42 in brain tissue, on the one hand clears Aβ amyloid plaques, reduces direct damage to neurons, reduces oxidative stress and cell apoptosis, thereby improving the living environment of neurons, greatly improving communication between neurons, and helping to restore cognitive function; on the other hand, it reduces the activation of microglia, reduces the brain inflammatory response caused by the accumulation of Aβ42 in brain tissue, inhibits inflammatory factors in the TLR4 / MyD88 / NLRP3 signaling pathway, and reduces damage to nerve cells; at the same time, reducing the concentration of Aβ42 greatly improves synaptic transmission, accelerates the recovery of normal function of the neural network, and effectively improves Alzheimer's disease. The bacteria can also regulate the imbalance of intestinal flora metabolites, reduce intestinal mucosal barrier damage in rats, improve intestinal barrier permeability, prevent the release and diffusion of harmful metabolites such as LPS, reduce the nucleation of Aβ aggregates, and then clear Aβ amyloid plaques to protect the nervous system and reduce brain neuroinflammatory response.

[0044] According to a second aspect of the present invention, a use of Bifidobacterium animalis subsp. lactis is provided. The Bifidobacterium animalis subsp. lactis can be used to prepare Bifidobacterium animalis subsp. lactis bacterial powder, Bifidobacterium animalis subsp. lactis postbiotics or medicines for protecting nerve cells.

[0045] In a preferred embodiment of the present invention, the method for preparing the animal Bifidobacterium lactis subspecies powder comprises the following steps:

[0046] First, prepare the fermentation liquid, lower the temperature of the centrifuge to 4~6°C, centrifuge the fermentation liquid at a centrifugal speed of 4000~6000rpm / min, and centrifuge for 20~30min. Take the precipitate after centrifugation, place it at -82~-80°C for pre-freezing for 2~3h, and then freeze-dry it at a drying temperature of -80~-60°C and a drying time of 24~48h to obtain animal Bifidobacterium lactis subspecies IOB-LO7 bacterial powder.

[0047] In a preferred embodiment of the present invention, the method for preparing animal Bifidobacterium lactis postbiotics comprises the following steps:

[0048] First, prepare the fermentation liquid, lower the temperature of the centrifuge to 4-6°C, centrifuge the fermentation liquid at a centrifugal speed of 4000-6000 rpm / min, and centrifuge for 20-30 minutes; sterilize the precipitate after centrifugation at 80-95°C for 20-25 minutes, place it at -82-80°C for pre-freezing for 2-3 hours, and then freeze-dry it to obtain animal Bifidobacterium lactis subsp. IOB-LO7 postbiotic powder; the drying temperature is set to -80-60°C, and the drying time is 24-48 hours.

[0049] In a preferred embodiment of the present invention, the method for preparing the fermentation broth comprises:

[0050] The animal Bifidobacterium lactis subsp. lactis 10B-LO7 stored in a cryopreservation tube is inoculated into 15-20 mL of TPY liquid culture medium, placed in a constant temperature incubator and strictly anaerobically cultured for 18-24 hours at a culture temperature of 35-38° C. to obtain a first-generation activated bacterial solution; the first-generation activated bacterial solution is inoculated into 50-60 mL of TPY liquid culture medium at an inoculation size of 3-5%, cultured at a temperature of 35-38° C., and strictly anaerobically cultured for 18-20 hours to obtain an activated bacterial solution; the activated bacterial solution is inoculated into 90-100 mL of TPY liquid culture medium at an inoculation size of 1-3%, cultured at a temperature of 35-38° C., and strictly anaerobically cultured for 18-20 hours to obtain a fermentation seed solution; the fermentation seed solution is inoculated into 800-1000 mL of TPY liquid culture medium at an inoculation size of 3-5%, cultured at a temperature of 35-38° C., and strictly anaerobically cultured for 18-20 hours to obtain a fermentation solution.

[0051] In the present invention, TPY liquid culture medium was purchased from Qingdao High-Tech Industrial Park Haibo Biotechnology Co., Ltd., with the drug number HBB570.

[0052] In the present invention, the preparation method of animal Bifidobacterium lactis subspecies powder specifically comprises:

[0053] The animal Bifidobacterium lactis subsp. lactis IOB-LO7 stored in a cryopreservation tube is inoculated into 15-20 mL of TPY liquid culture medium, placed in a constant temperature incubator and cultured strictly anaerobically for 18-24 hours at a culture temperature of 35-38° C. to obtain a first-generation activated bacterial solution; the first-generation activated bacterial solution is inoculated into 50-60 mL of liquid culture medium at an inoculation size of 3-5%, cultured at a temperature of 35-38° C., and cultured strictly anaerobically for 18-20 hours to obtain an activated bacterial solution; the activated bacterial solution is inoculated into 90-100 mL of liquid culture medium at an inoculation size of 1-3%, cultured at a temperature of 35-38° C., and cultured strictly anaerobically for 18-20 hours to obtain a fermentation seed solution; the fermentation seed solution is inoculated into 800-1000 mL of liquid culture medium at an inoculation size of 3-5%, cultured at a temperature of 35-38° C., and cultured strictly anaerobically for 18-20 hours to obtain a fermentation solution.

[0054] The temperature of the centrifuge was lowered to 4-6°C, and the fermentation broth was centrifuged at a speed of 4000-6000 rpm / min for 20-30 min. The precipitate after centrifugation was taken and placed at -82-80°C for pre-freezing for 2-3 h, and then freeze-dried at a drying temperature of -80-60°C for 24-48 h to obtain animal Bifidobacterium lactis subsp. IOB-LO7 bacterial powder.

[0055] In the present invention, the preparation method of animal Bifidobacterium lactis postbiotics specifically includes:

[0056] The animal Bifidobacterium lactis subsp. lactis IOB-LO7 stored in a cryopreservation tube is inoculated into 15-20 mL of TPY liquid culture medium, placed in a constant temperature incubator and cultured strictly anaerobically for 18-24 hours at a culture temperature of 35-38° C. to obtain a first-generation activated bacterial solution; the first-generation activated bacterial solution is inoculated into 50-60 mL of liquid culture medium at an inoculation size of 3-5%, cultured at a temperature of 35-38° C., and cultured strictly anaerobically for 18-20 hours to obtain an activated bacterial solution; the activated bacterial solution is inoculated into 90-100 mL of liquid culture medium at an inoculation size of 1-3%, cultured at a temperature of 35-38° C., and cultured strictly anaerobically for 18-20 hours to obtain a fermentation seed solution; the fermentation seed solution is inoculated into 800-1000 mL of liquid culture medium at an inoculation size of 3-5%, cultured at a temperature of 35-38° C., and cultured strictly anaerobically for 18-20 hours to obtain a fermentation solution.

[0057] The temperature of the centrifuge is lowered to 4-6°C, and the fermentation broth is centrifuged at a speed of 4000-6000 rpm / min for 20-30 min. The precipitate after centrifugation is sterilized at 80-95°C for 20-25 min, and then placed at -82-80°C for pre-freezing for 2-3 h, and then freeze-dried to obtain animal Bifidobacterium lactis subsp. IOB-LO7 postbiotic powder; the drying temperature is set to -80-60°C, and the drying time is 24-48 h.

[0058] In a preferred embodiment of the present invention, the drug for protecting nerve cells comprises Bifidobacterium animalis subsp. lactis, Bifidobacterium animalis subsp. lactis bacterial powder or Bifidobacterium animalis subsp. lactis postbiotics.

[0059] In the present invention, the medicine for protecting nerve cells comprises, for example, Bifidobacterium animalis subsp. lactis powder, Bifidobacterium animalis subsp. lactis postbiotics, or Bifidobacterium animalis subsp. lactis powder and Bifidobacterium animalis subsp. lactis postbiotics.

[0060] In a preferred embodiment of the present invention, the viable cell count of the animal Bifidobacterium lactis subsp. 9 ~8×10 11 cfu / g, the number of viable bacteria of drugs that protect nerve cells is 1×109 ~8×10 11 cfu / g.

[0061] In order to further illustrate the technical means and effects adopted by the present invention, the technical solutions of the present invention are further described below in conjunction with the preferred embodiments of the present invention, but the present invention is not limited to the scope of the embodiments.

[0062] Healthy SPF Wistar rats were randomly divided into five groups (10 rats each): a control group, a model group, a positive drug group (administered orally with donepezil hydrochloride), an IOB-LO7 bacterial powder group, and an IOB-LO7 postbiotic group. Four of the other groups, excluding the control group, received intraperitoneal injections of D-galactose (90 mg / kg / day) and oral administration of AlCl₃ (40 mg / kg / day) for 13 consecutive weeks to establish an Alzheimer's disease model.

[0063] One hour after the intraperitoneal injection of D-galactose and oral gavage of AlCl3, the control group and the model group were gavaged with sterile saline (0.5 mL / animal), the positive drug control group was gavaged with donepezil hydrochloride (0.85 mg / kg / day, 0.5 mL / animal), and the bacterial powder intervention group was gavaged with the corresponding dose of bacterial powder (1×10 9 CFU / kg), the postbiotic intervention group was gavaged with the corresponding dose of postbiotics (1×10 9 CFU / kg), treated by oral gavage for 3 months.

[0064] Example 1

[0065] Bifidobacterium animalis subsp. lactis IOB-LO7 improves behavioral parameters in rats with Alzheimer's disease

[0066] (1) Morris water maze test

[0067] The experiment was conducted for 5 consecutive days of training, with four different starting points (different quadrants) trained every day. This was a positioning navigation test. 24 hours after the positioning navigation test, the underwater platform was removed and the rat was placed into the water at the same entry point. The number of times the rat crossed the platform within 60 seconds was recorded to determine the rat's memory ability.

[0068] The experimental results are as follows Figure 1 As shown in the figure, compared with the control group, the number of times the model group rats crossed the platform decreased significantly, indicating that aluminum chloride combined with D-galactose can cause memory impairment. Compared with the model group, the number of times the positive drug group, the IOB-LO7 bacterial powder group, and the IOB-LO7 postbiotic group crossed the platform increased.

[0069] (2) Open Field Test (OFT)

[0070] The experimental apparatus consisted of four square boxes (0.8m×0.8m×0.5m) made of plastic. A trajectory recording device was placed directly above the box to track movement in real time, recording the total distance, average speed, and number of activities of the rat in the box within 5 minutes.

[0071] The anxiety state of animals with Alzheimer's disease was reflected by monitoring their autonomous activity and exploratory behavior. Figure 2 、 Figure 3 and Figure 4 As shown, Figure 2 The figure shows the average speed of rats in the open field experiment. It can be seen from the figure that compared with the control group, the average speed of the rats in the model group was significantly reduced. Compared with the model group, the average speed of the positive drug group, IOB-LO7 bacterial powder group and postbiotic group was significantly increased. Figure 3 The figure shows the total distance traveled by rats in the open field experiment. Compared with the control group, the total distance traveled by rats in the model group was significantly reduced. Compared with the model group, the total distance traveled by rats in the positive drug group, IOB-LO7 bacterial powder group and postbiotic group was significantly increased. Figure 4 The results of the open field experiment show that the number of activities of rats in the model group was significantly reduced compared with the control group. Compared with the model group, the number of activities of rats in the positive drug group, IOB-LO7 bacterial powder group and postbiotic group was significantly increased.

[0072] In summary, the experimental results show that IOB-LO7 postbiotics can improve the anxiety-like behavior of Alzheimer's rats induced by D-galactose / AlCl3.

[0073] Example 2

[0074] Effects of Bifidobacterium animalis subsp. lactis IOB-LO7 on Aβ42 concentration in the brain of rats with Alzheimer's disease

[0075] After 3 months of oral gavage treatment with Shengyuan and positive drugs, the Aβ42 levels of rats in the samples were determined using an Aβ42 enzyme-linked immunosorbent assay (ELISA) kit.

[0076] Experimental Materials:

[0077] Aβ42 enzyme-linked immunosorbent assay ELISA kit was purchased from Nanjing Herbal Source Biotechnology Co., Ltd.

[0078] Experimental process:

[0079] The purified rat Aβ42 protein capture antibody was coated on the microplate to make a solid-phase antibody. The rat Aβ42 protein was then added to the microplate and then combined with the HRP-labeled detection antibody. After thorough washing, TMB colorimetric reagent was added and the absorbance (OD value) was measured at 450 nm using a microplate reader. The rat Aβ42 content was determined using the standard curve. The experimental results are shown in Table 1. Figure 5 and Figure 6 The results are as follows: Table 1 shows the Aβ42 content data of rat brains. Each group is the average value of multiple rat samples. Figure 5 The results of Aβ42 content in rat hippocampus show that compared with the control group, the amount of Aβ42 deposited in the model group was significantly increased (76.88 ng / L). Compared with the model group, the amount of Aβ42 deposited in the hippocampus of the IOB-LO7 bacterial powder group and the postbiotic group was significantly reduced (44.57 ng / L and 39.50 ng / L). According to the calculation formula, the reduction rate (%) = (model group ~ experimental group) / model group × 100%, among which the bacterial powder group decreased by 42.1%, and the postbiotic group decreased by 48.6%. Figure 6 The results of Aβ42 content in the cerebral cortex are shown in Figure 2. Figure 6 Compared with the control group, the Aβ42 content in the cerebral cortex of the model group was significantly increased (66.08 ng / L). Compared with the model group, the Aβ42 content in the cerebral cortex of the IOB-LO7 bacterial powder group and the postbiotic group was significantly decreased (29.96 ng / L and 23.23 ng / L). According to the reduction rate calculation formula, the Aβ42 content in the bacterial powder group decreased by 54.6%, and the postbiotic group decreased by 64.9%.

[0080] The above data show that animal Bifidobacterium lactis subsp. IOB-LO7 can reduce the Aβ42 content in the brain of rats with Alzheimer's disease.

[0081] Table 1 Aβ42 content in rat brain

[0082]

[0083] Example 3

[0084] Clearance of Aβ amyloid plaques in the brains of rats with Alzheimer's disease by Bifidobacterium animalis subsp. lactis IOB-LO7

[0085] Immunofluorescence labeling was used to observe the expression of Aβ42 in the hippocampus.

[0086] Experimental materials: xylene, purchased from Shanghai Lingfeng Chemical Reagent Co., Ltd.; anhydrous ethanol, purchased from Tianjin Jiangtian Chemical Technology Co., Ltd.; EDTA (pH 8.0) antigen retrieval solution, PBS buffer, histochemical pen, BSA, primary antibody Iba~1+A, DAPI, autofluorescence quencher, and anti-fluorescence quenching mounting medium, purchased from Wuhan Sewell Biotechnology Co., Ltd.

[0087] The experimental method is as follows:

[0088] (1) Dewaxing of paraffin sections: Immerse the paraffin sections in xylene I solution for 15 minutes, then place the sections in xylene II solution for 15 minutes, then immerse the sections in anhydrous ethanol I for 5 minutes, then replace with anhydrous ethanol II for 5 minutes, then immerse in 85% and 75% alcohol for 5 minutes each, and finally rinse with pure distilled water.

[0089] (2) Antigen retrieval: Place the above sections in a microwave oven filled with EDTA antigen retrieval solution (pH 8.0). Bring to a boil, stop heating for 8 minutes, and then heat on low heat for 7 minutes. Avoid drying the sections during the heating process. Allow the sections to cool naturally to room temperature and decolorize them three times with PBS solution (pH 7.4).

[0090] (3) Circle serum blocking: When the slices are slightly dry, use a histochemical pen to draw circles around the tissue, then dry the slices, add BSA to the tissue, and block for 30 minutes.

[0091] (4) Add primary antibody: Gently remove the blocking solution on the slice, then add the primary antibody prepared with PBS, and place the slice in a humidified chamber and incubate overnight at 4°C.

[0092] (5) Counterstaining the cell nucleus with DAPI stain: Decolorize the above sections with PBS (pH 7.4) three times. After the sections are dried, add DAPI solution and incubate at room temperature in the dark for 10 minutes.

[0093] (6) Quenching tissue autofluorescence: Decolorize the above sections with PBS (pH 7.4) three times. After the sections are dried, add autofluorescence quencher to the tissue and incubate for 5 minutes. Rinse the tissue sections with running water for 10 minutes.

[0094] (7) Sealing: After the slices are dried, anti-fluorescence quenching sealing agent is added dropwise for sealing.

[0095] (8) Microscopic examination and photography: The processed tissue sections were observed for fluorescence brightness using an inverted fluorescence microscope and photographed.

[0096] The results are as follows Figure 7 and Figure 8As shown, minimal Aβ42 was present in the hippocampus of the control group, with occasional red fluorescent plaques. However, Aβ42 expression was high in the hippocampus of the model group, with numerous red plaques deposited. ImageJ analysis quantified the concentration to be 313.1%, and the fluorescence intensity was high. After three months of intervention, Aβ42 expression in the hippocampus of rats in the IOB-LO7 bacterial powder and postbiotic groups decreased, and the area of ​​Aβ42 plaques in the hippocampus was significantly reduced. ImageJ analysis quantified the concentration to be 205.8% and 187.3%, respectively. According to the reduction rate calculation formula (reduction rate (%) = (model group - experimental group) / model group × 100%), the bacterial powder group decreased by 34.3%, and the postbiotic group decreased by 40.2%. The immunofluorescence results were consistent with the ELISA results for Aβ42 levels in the hippocampus.

[0097] Example 4

[0098] Bifidobacterium animalis subsp. lactis IOB-LO7 postbiotics and bacterial powder inhibit the TLR4 / NLRP3 / MyD88 signaling pathway and alleviate neuroinflammatory responses.

[0099] Toll-like receptor 4 (TLR4) is a type I transmembrane receptor that senses exogenous pathogens and endogenous inflammatory stimuli in the brain, including Aβ and LPS. TLR4 / NLRP3 / MyD88 signaling can trigger an inflammatory response in the brain, promoting the transcriptional activity of nuclear factor-β and ultimately leading to the expression of the proinflammatory cytokines IL-1β and IL-18. The relative transcript levels of NLRP3, MyD88, IL-1β, and IL-18 in rat brain tissue were measured to investigate the expression patterns of genes involved in the TLR4 signaling pathway and the degree of transcription factor activation.

[0100] Experimental materials: 2X Universal SYBR Green Fast qPCR Mix (5 mL), AB Script Neo RT Master Mix for qPCR with gDNA Remover (100 T), purchased from Wuhan Aibote Biotechnology Co., Ltd.; Trizol (total RNA extraction reagent, 100 mL), purchased from Tianjin Jiangtian Chemical Technology Co., Ltd.

[0101] The experimental procedure is as follows: 50-100 mg of rat brain tissue sample was taken, and 1 mL of Trizol was added to quickly grind and extract RNA. Reverse transcription was performed to synthesize cDNA according to the AB Script Neo RT Master Mix for qPCR with gDNA Remover Kit protocol. The reaction solution was prepared according to the 2X Universal SYBR Green Fast qPCR Mix Kit, and amplification was performed using a real-time fluorescence quantitative PCR system. Primer information is shown in Table 2. Reaction conditions: 95°C pre-denaturation for 3 minutes; 95°C denaturation for 15 seconds; 60°C annealing for 30 seconds, 40 cycles, according to 2 -ΔΔCt The formula was used to calculate the relative transcription level of the target gene mRNA in the sample.

[0102] Table 2 Design of primer sequences for real-time fluorescence quantitative PCR

[0103]

[0104] The results are as follows Figure 9 、 Figure 10 、 Figure 11 、 Figure 12 and Figure 13 As shown, compared with the control group, the relative expression levels of TLR4, NLRP3, MyD88, IL-1β, and IL-18 in the model group were significantly increased. The positive drug group significantly differentiated from the model group and significantly downregulated the relative transcription levels of TLR4, NLRP3, MyD88, IL-1β, and IL-18. Similar to the positive drug group, the IOB-LO7 postbiotic group and bacterial powder group also significantly downregulated the expression of TLR4, NLRP3, MyD88, IL-1β, and IL-18-related genes compared with the model group. The expression levels of IL-1β and IL-18-related genes in the postbiotic group decreased by 19.7% and 56.2%, respectively, while those in the bacterial powder group decreased by 9.4% and 28.8%.

[0105] Therefore, the results showed that both animal Bifidobacterium lactis subsp. IOB-LO7 postbiotics and bacterial powder can inhibit the TLR4 / MyD88 / NLRP3 signaling pathway and alleviate neuroinflammation in Alzheimer's rats.

[0106] Example 5

[0107] Bifidobacterium animalis subsp. lactis IOB-LO7 postbiotic reduces LPS levels in the intestinal contents, serum, and hippocampus of Alzheimer's disease rats

[0108] Experimental materials: Rat lipopolysaccharide (LPS) ELISA kit Nanjing Herbal Source Biotechnology Co., Ltd.

[0109] Rat lipopolysaccharide (LPS) ELISA kit was used to measure the levels of LPS in rat intestinal contents, serum, and brain tissue.

[0110] Figure 14 The LPS content in rat feces was significantly increased in the intestinal contents of the model group compared with the control group. Compared with the model group, the LPS content in the positive drug group, IOB-LO7 bacterial powder and postbiotic group showed a downward trend. Figure 15 The LPS content in the serum of rats in each group showed that compared with the control group, the LPS level in the serum of the model group was significantly increased. Compared with the model group, the LPS levels in the serum of the positive drug group, IOB-LO7 bacterial powder group and postbiotic group were significantly decreased. Figure 16 is the LPS content in the hippocampus of rats in each group. It can be seen that compared with the control group, the LPS level in the brain tissue of the model group was significantly increased, and the LPS levels in the brain tissue of the positive drug group, IOB-LO7 bacterial powder group and postbiotic group showed a significant downward trend.

[0111] The pathological sections of the rat small intestine tissue were further analyzed to observe the changes in the morphological structure of the rat intestinal tissue. Figure 17 As shown in the figure, compared with the control group, the small intestinal villi of the model group rats were significantly shortened or even atrophied, with sparse arrangement and a relatively chaotic tissue structure. After the bacterial powder and postbiotic intervention, although the villi at the top of the colon of rats in each group were slightly lost, the length of the villi at the bottom increased, and the tissue structure became clearer. This shows that postbiotics can improve the small intestinal tissue morphology of AD rats to a certain extent, effectively maintain the small intestinal mucosal structure, and have a certain protective effect on small intestinal tissue damage.

[0112] In summary, supplementation with IOB-LO7 bacterial powder or postbiotics can alleviate intestinal mucosal barrier damage in AD rats and prevent the release and diffusion of harmful metabolites such as LPS.

Claims

1. A Bifidobacterium animalis subsp. lactis that reduces Aβ42 deposition, It is characterized in that The name of the animal Bifidobacterium lactis subspecies is animal Bifidobacterium lactis subspecies IOB-LO7, which is classified as Bifidobacterium animalis subsp.lactis , and was deposited in the General Microbiology Center of China Microorganism Culture Collection Administration, abbreviated as CGMCC, on December 23, 2021, with the deposit number CGMCCNo.24185.

2. A use of Bifidobacterium animalis subsp. lactis as claimed in claim 1, It is characterized in that The animal Bifidobacterium lactis subspecies can be used to prepare animal Bifidobacterium lactis subspecies bacterial powder, animal Bifidobacterium lactis subspecies postbiotics or medicines for protecting nerve cells.

3. The use of Bifidobacterium lactis subsp. animalis as claimed in claim 2, It is characterized in that The preparation method of the animal Bifidobacterium lactis subspecies powder comprises the following steps: First, prepare the fermentation liquid, lower the temperature of the centrifuge to 4-6°C, centrifuge the fermentation liquid at a centrifugal speed of 4000-6000 rpm / min, and centrifuge for 20-30 minutes. Take the precipitate after centrifugation, place it at -82-80°C for pre-freezing for 2-3 hours, and then freeze-dry it at a drying temperature of -80-60°C for 24-48 hours to obtain animal Bifidobacterium lactis subspecies IOB-LO7 bacterial powder.

4. The use of Bifidobacterium animalis subsp. lactis as claimed in claim 2, It is characterized in that The method for preparing animal Bifidobacterium lactis postbiotics comprises the following steps: First, prepare the fermentation liquid, lower the temperature of the centrifuge to 4-6°C, centrifuge the fermentation liquid at a centrifugal speed of 4000-6000 rpm / min, and centrifuge for 20-30 min; sterilize the precipitate after centrifugation at 80-95°C for 20-25 min, place it at -82-80°C for pre-freezing for 2-3 h, and then freeze-dry it to obtain animal Bifidobacterium lactis subspecies IOB-LO7 postbiotic powder; the drying temperature is set to -80-60°C, and the drying time is 24-48 h.

5. The use of Bifidobacterium animalis subsp. lactis as claimed in any one of claims 3 to 4, It is characterized in that The method for preparing the fermentation broth comprises: The animal Bifidobacterium lactis subsp. IOB-LO7 stored in a cryopreservation tube is inoculated into 15-20 mL of TPY liquid culture medium, placed in a constant temperature incubator for strict anaerobic culture for 18-24 hours at a culture temperature of 35-38° C., to obtain a first-generation activated bacterial solution; the first-generation activated bacterial solution is inoculated into 50-60 mL of TPY liquid culture medium at an inoculation amount of 3-5%, the culture temperature is 35-38° C., and the culture is strictly anaerobic for 18-24 hours to obtain an activated bacterial solution; the activated bacterial solution is inoculated into 90-100 mL of TPY liquid culture medium at an inoculation amount of 1-3%, the culture temperature is 35-38° C., and the culture is strictly anaerobic for 18-20 hours to obtain a fermentation seed solution; the fermentation seed solution is inoculated into 800-1000 mL of TPY liquid culture medium at an inoculation amount of 3-5%, the culture temperature is 35-38° C., and the culture is strictly anaerobic for 18-20 hours to obtain a fermentation solution.

6. The use of Bifidobacterium animalis subsp. lactis as claimed in claim 2, It is characterized in that The medicine for protecting nerve cells comprises Bifidobacterium animalis subspecies lactis, Bifidobacterium animalis subspecies lactis bacterial powder or Bifidobacterium animalis subspecies lactis postbiotics.

7. The use of Bifidobacterium animalis subsp. lactis as claimed in claim 2, It is characterized in that The viable bacteria count of the animal Bifidobacterium lactis subspecies powder is 1×10 9 ~8×10 11 cfu / g, the number of viable bacteria of drugs that protect nerve cells is 1×10 9 ~8×10 11 cfu / g.